Scarica l'app Stockscreener
1.56
4.88%
-0.08
Dopo l'orario di chiusura:
1.61
0.05
+3.21%
Precedente Chiudi:
$1.64
Aprire:
$1.66
Volume 24 ore:
752.10K
Relative Volume:
0.38
Capitalizzazione di mercato:
$49.95M
Reddito:
-
Utile/perdita netta:
$-51.50M
Rapporto P/E:
-0.39
EPS:
-4
Flusso di cassa netto:
$-47.10M
1 W Prestazione:
-16.58%
1M Prestazione:
-32.03%
6M Prestazione:
-78.54%
1 anno Prestazione:
-81.34%
Intervallo 1D:
$1.53
$1.68
Intervallo di 1 settimana:
$1.53
$1.88
Portata 52W:
$0.87
$12.85
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Confronta OTLK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.56 | 49.95M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Research Analysts Set Expectations for OTLK Q2 Earnings - MarketBeat
HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World
Q1 Earnings Estimate for OTLK Issued By HC Wainwright - MarketBeat
What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World
Outlook Therapeutics® Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Can This First-Ever Approved Ophthalmic Bevacizumab Transform Eye Treatment in 2025? - StockTitan
Outlook Therapeutics' (OTLK) Neutral Rating Reaffirmed at Chardan Capital - MarketBeat
Outlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC Wainwright - MarketBeat
Outlook Therapeutics (NASDAQ:OTLK) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World
Outlook Therapeutics’ (OTLK) Neutral Rating Reaffirmed at Chardan Capital - Armenian Reporter
Outlook Therapeutics (NASDAQ:OTLK) Given “Neutral” Rating at Chardan Capital - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Outlook Therapeutics stock target cut to $3 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Outlook Therapeutics stock target cut to $3 at H.C. Wainwright - Investing.com India
Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
ONS-5010 shows promise in wet AMD treatment, matching Lucentis - MSN
Outlook Therapeutics Reports Strong Earnings and Strategic Progress - MSN
Analyzing Scilex (NASDAQ:SCLX) and Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook Therapeutics Reports Financial Results For First Quarter Of 2025 -February 14, 2025 at 09:07 am EST - Marketscreener.com
Outlook Therapeutics Secures Funding and Board Restructures - MSN
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2025 - TradingView
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2024 - Marketscreener.com
Outlook Therapeutics Advances ONS-5010 / LYTENAVA™ BLA Resubmission and Prepares for European Commercial Launch in 2025 - Nasdaq
Outlook Reports Stunning Earnings Turnaround: From $11.2M Loss to $17.4M Profit as European Launch Approaches - StockTitan
Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $27.40 - MarketBeat
Outlook Therapeutics (OTLK) to Release Earnings on Wednesday - MarketBeat
Strategic Move: Biologics Deal-Making Veteran Takes CBO Role at Sonnet BioTherapeutics - StockTitan
Outlook Therapeutics (OTLK) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $27.40 Consensus Target Price from Analysts - Defense World
Outlook Therapeutics (OTLK) Expected to Announce Earnings on Wednesday - MarketBeat
Outlook Therapeutics Inc (NASDAQ: OTLK) Has Succeeded In Attracting Investors This Year, The Stock Is Down -9.52% Year-To-Date – Marketing Sentinel - Marketing Sentinel
Holdings of Outlook Therapeutics Inc (OTLK) are aligned with the stars - SETE News
Outlook Therapeutics Inc (OTLK) produces promising results - US Post News
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Outlook Therapeutics Inc (OTLK) receives a Neutral rating from Chardan Capital Markets - Knox Daily
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):